Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.

Gordon CM, Cleveland RH, Baltrusaitis K, Massaro J, D'Agostino RB Sr, Liang MG, Snyder B, Walters M, Li X, Braddock DT, Kleinman ME, Kieran MW, Gordon LB.

Bone. 2019 Aug;125:103-111. doi: 10.1016/j.bone.2019.05.008. Epub 2019 May 8.

PMID:
31077852
2.

Hutchinson-Gilford Progeria Syndrome.

Gordon LB, Brown WT, Collins FS.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2003 Dec 12 [updated 2019 Jan 17].

3.

Analyses of LMNA-negative juvenile progeroid cases confirms biallelic POLR3A mutations in Wiedemann-Rautenstrauch-like syndrome and expands the phenotypic spectrum of PYCR1 mutations.

Lessel D, Ozel AB, Campbell SE, Saadi A, Arlt MF, McSweeney KM, Plaiasu V, Szakszon K, Szőllős A, Rusu C, Rojas AJ, Lopez-Valdez J, Thiele H, Nürnberg P, Nickerson DA, Bamshad MJ, Li JZ, Kubisch C, Glover TW, Gordon LB.

Hum Genet. 2018 Dec;137(11-12):921-939. doi: 10.1007/s00439-018-1957-1. Epub 2018 Nov 19.

4.

Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.

Gordon LB, Shappell H, Massaro J, D'Agostino RB Sr, Brazier J, Campbell SE, Kleinman ME, Kieran MW.

JAMA. 2018 Apr 24;319(16):1687-1695. doi: 10.1001/jama.2018.3264.

5.

Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts.

DuBose AJ, Lichtenstein ST, Petrash NM, Erdos MR, Gordon LB, Collins FS.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):4206-4211. doi: 10.1073/pnas.1802811115. Epub 2018 Mar 26. Erratum in: Proc Natl Acad Sci U S A. 2018 Apr 16;:.

6.

Microbiome at sites of gingival recession in children with Hutchinson-Gilford progeria syndrome.

Bassir SH, Chase I, Paster BJ, Gordon LB, Kleinman ME, Kieran MW, Kim DM, Sonis A.

J Periodontol. 2018 Jun;89(6):635-644. doi: 10.1002/JPER.17-0351.

7.

Cardiac Abnormalities in Patients With Hutchinson-Gilford Progeria Syndrome.

Prakash A, Gordon LB, Kleinman ME, Gurary EB, Massaro J, D'Agostino R Sr, Kieran MW, Gerhard-Herman M, Smoot L.

JAMA Cardiol. 2018 Apr 1;3(4):326-334. doi: 10.1001/jamacardio.2017.5235.

8.

Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib.

Gordon LB, Campbell SE, Massaro JM, D'Agostino RB Sr, Kleinman ME, Kieran MW, Moses MA.

Pediatr Res. 2018 May;83(5):982-992. doi: 10.1038/pr.2018.9. Epub 2018 Feb 28.

PMID:
29342131
9.

Pubertal Progression in Female Adolescents with Progeria.

Greer MM, Kleinman ME, Gordon LB, Massaro J, D'Agostino RB Sr, Baltrusaitis K, Kieran MW, Gordon CM.

J Pediatr Adolesc Gynecol. 2018 Jun;31(3):238-241. doi: 10.1016/j.jpag.2017.12.005. Epub 2017 Dec 16.

10.

Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts.

Gabriel D, Shafry DD, Gordon LB, Djabali K.

Oncotarget. 2017 Jul 18;8(39):64809-64826. doi: 10.18632/oncotarget.19363. eCollection 2017 Sep 12.

11.

Ophthalmologic Features of Progeria.

Mantagos IS, Kleinman ME, Kieran MW, Gordon LB.

Am J Ophthalmol. 2017 Oct;182:126-132. doi: 10.1016/j.ajo.2017.07.020. Epub 2017 Jul 27.

PMID:
28756152
12.

Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype.

Gabriel D, Gordon LB, Djabali K.

PLoS One. 2016 Dec 29;11(12):e0168988. doi: 10.1371/journal.pone.0168988. eCollection 2016.

13.

A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome.

Bar DZ, Arlt MF, Brazier JF, Norris WE, Campbell SE, Chines P, Larrieu D, Jackson SP, Collins FS, Glover TW, Gordon LB.

J Med Genet. 2017 Mar;54(3):212-216. doi: 10.1136/jmedgenet-2016-104295. Epub 2016 Dec 5.

14.

Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations.

Rivera-Torres J, Calvo CJ, Llach A, Guzmán-Martínez G, Caballero R, González-Gómez C, Jiménez-Borreguero LJ, Guadix JA, Osorio FG, López-Otín C, Herraiz-Martínez A, Cabello N, Vallmitjana A, Benítez R, Gordon LB, Jalife J, Pérez-Pomares JM, Tamargo J, Delpón E, Hove-Madsen L, Filgueiras-Rama D, Andrés V.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7250-E7259. Epub 2016 Oct 31.

15.

Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.

Gordon LB, Kleinman ME, Massaro J, D'Agostino RB Sr, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW.

Circulation. 2016 Jul 12;134(2):114-25. doi: 10.1161/CIRCULATIONAHA.116.022188.

16.

The decision-making process and criteria in selecting candidate drugs for progeria clinical trials.

Gordon LB, Kieran MW, Kleinman ME, Misteli T.

EMBO Mol Med. 2016 Jul 1;8(7):685-7. doi: 10.15252/emmm.201606280. Print 2016 Jul. No abstract available.

17.

Hutchinson-Gilford progeria syndrome.

Ullrich NJ, Gordon LB.

Handb Clin Neurol. 2015;132:249-64. doi: 10.1016/B978-0-444-62702-5.00018-4. Review.

PMID:
26564085
18.

Atherosclerosis in ancient humans, accelerated aging syndromes and normal aging: is lamin a protein a common link?

Miyamoto MI, Djabali K, Gordon LB.

Glob Heart. 2014 Jun;9(2):211-8. doi: 10.1016/j.gheart.2014.04.001. Review.

19.

Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.

Gabriel D, Roedl D, Gordon LB, Djabali K.

Aging Cell. 2015 Feb;14(1):78-91. doi: 10.1111/acel.12300. Epub 2014 Dec 16.

20.

Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.

Gordon LB, Massaro J, D'Agostino RB Sr, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW; Progeria Clinical Trials Collaborative.

Circulation. 2014 Jul 1;130(1):27-34. doi: 10.1161/CIRCULATIONAHA.113.008285. Epub 2014 May 2.

21.

Progeria: a paradigm for translational medicine.

Gordon LB, Rothman FG, López-Otín C, Misteli T.

Cell. 2014 Jan 30;156(3):400-7. doi: 10.1016/j.cell.2013.12.028.

22.

Initial cutaneous manifestations of Hutchinson-Gilford progeria syndrome.

Rork JF, Huang JT, Gordon LB, Kleinman M, Kieran MW, Liang MG.

Pediatr Dermatol. 2014 Mar-Apr;31(2):196-202. doi: 10.1111/pde.12284. Epub 2014 Jan 24.

23.

Median and ulnar neuropathies in U.S. Army Medical Command Band members.

Shaffer SW, Koreerat NR, Gordon LB, Santillo DR, Moore JH, Greathouse DG.

Med Probl Perform Art. 2013 Dec;28(4):188-94.

PMID:
24337029
24.

Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment.

Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman ME.

Neurology. 2013 Jul 30;81(5):427-30. doi: 10.1212/WNL.0b013e31829d85c0. Epub 2013 Jun 28.

25.

Overtreatment of presumed urinary tract infection in older women presenting to the emergency department.

Gordon LB, Waxman MJ, Ragsdale L, Mermel LA.

J Am Geriatr Soc. 2013 May;61(5):788-92. doi: 10.1111/jgs.12203. Epub 2013 Apr 16.

PMID:
23590846
26.

Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo.

Wenzel V, Roedl D, Gabriel D, Gordon LB, Herlyn M, Schneider R, Ring J, Djabali K.

Biol Open. 2012 Jun 15;1(6):516-26. doi: 10.1242/bio.20121149. Epub 2012 Apr 16.

27.

Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome.

Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ.

AJNR Am J Neuroradiol. 2013 May;34(5):1091-7. doi: 10.3174/ajnr.A3341. Epub 2012 Nov 22.

28.

Progeria: translational insights from cell biology.

Gordon LB, Cao K, Collins FS.

J Cell Biol. 2012 Oct 1;199(1):9-13. doi: 10.1083/jcb.201207072.

29.

Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.

Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, Ploski C, Correia A, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16666-71. doi: 10.1073/pnas.1202529109. Epub 2012 Sep 24.

30.

A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome.

Cleveland RH, Gordon LB, Kleinman ME, Miller DT, Gordon CM, Snyder BD, Nazarian A, Giobbie-Hurder A, Neuberg D, Kieran MW.

Pediatr Radiol. 2012 Sep;42(9):1089-98. doi: 10.1007/s00247-012-2423-1. Epub 2012 Jul 1.

31.

Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome.

Ullrich NJ, Silvera VM, Campbell SE, Gordon LB.

AJNR Am J Neuroradiol. 2012 Sep;33(8):1512-8. doi: 10.3174/ajnr.A3088. Epub 2012 Mar 29.

32.

Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome.

Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB.

Hypertension. 2012 Jan;59(1):92-7. doi: 10.1161/HYPERTENSIONAHA.111.180919. Epub 2011 Nov 14.

33.

Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome.

Harten IA, Zahr RS, Lemire JM, Machan JT, Moses MA, Doiron RJ, Curatolo AS, Rothman FG, Wight TN, Toole BP, Gordon LB.

J Gerontol A Biol Sci Med Sci. 2011 Nov;66(11):1201-7. doi: 10.1093/gerona/glr137. Epub 2011 Aug 17.

34.

Hutchinson-Gilford progeria is a skeletal dysplasia.

Gordon CM, Gordon LB, Snyder BD, Nazarian A, Quinn N, Huh S, Giobbie-Hurder A, Neuberg D, Cleveland R, Kleinman M, Miller DT, Kieran MW.

J Bone Miner Res. 2011 Jul;26(7):1670-9. doi: 10.1002/jbmr.392.

35.

Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging.

Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, Erdos MR, Blair C, Funke B, Smoot L, Gerhard-Herman M, Machan JT, Kutys R, Virmani R, Collins FS, Wight TN, Nabel EG, Gordon LB.

Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2301-9. doi: 10.1161/ATVBAHA.110.209460. Epub 2010 Aug 26.

36.

Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition.

Marji J, O'Donoghue SI, McClintock D, Satagopam VP, Schneider R, Ratner D, Worman HJ, Gordon LB, Djabali K.

PLoS One. 2010 Jun 15;5(6):e11132. doi: 10.1371/journal.pone.0011132.

37.

Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes.

Domingo DL, Trujillo MI, Council SE, Merideth MA, Gordon LB, Wu T, Introne WJ, Gahl WA, Hart TC.

Oral Dis. 2009 Apr;15(3):187-95. doi: 10.1111/j.1601-0825.2009.01521.x. Epub 2009 Feb 19.

38.

Highlights of the 2007 Progeria Research Foundation scientific workshop: progress in translational science.

Gordon LB, Harling-Berg CJ, Rothman FG.

J Gerontol A Biol Sci Med Sci. 2008 Aug;63(8):777-87. No abstract available.

PMID:
18772465
39.

Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.

Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG; Childhood Myositis Heterogeneity Study Group.

Medicine (Baltimore). 2008 Mar;87(2):70-86. doi: 10.1097/MD.0b013e31816bc604.

40.

Phenotype and course of Hutchinson-Gilford progeria syndrome.

Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO 3rd, Gahl WA, Introne WJ.

N Engl J Med. 2008 Feb 7;358(6):592-604. doi: 10.1056/NEJMoa0706898.

41.

The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin.

McClintock D, Ratner D, Lokuge M, Owens DM, Gordon LB, Collins FS, Djabali K.

PLoS One. 2007 Dec 5;2(12):e1269.

42.

Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development.

Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, Kieran MW.

Pediatrics. 2007 Oct;120(4):824-33.

PMID:
17908770
43.

Aggrecan expression is substantially and abnormally upregulated in Hutchinson-Gilford Progeria Syndrome dermal fibroblasts.

Lemire JM, Patis C, Gordon LB, Sandy JD, Toole BP, Weiss AS.

Mech Ageing Dev. 2006 Aug;127(8):660-9. Epub 2006 May 2.

PMID:
16650460
44.

Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome.

Varga R, Eriksson M, Erdos MR, Olive M, Harten I, Kolodgie F, Capell BC, Cheng J, Faddah D, Perkins S, Avallone H, San H, Qu X, Ganesh S, Gordon LB, Virmani R, Wight TN, Nabel EG, Collins FS.

Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3250-5. Epub 2006 Feb 21.

45.

Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.

McClintock D, Gordon LB, Djabali K.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2154-9. Epub 2006 Feb 6.

46.

Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.

Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS.

Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12879-84. Epub 2005 Aug 29.

48.

Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome.

Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R, Collins FS.

Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8963-8. Epub 2004 Jun 7.

49.

Comparing the effectiveness of process-experiential with cognitive-behavioral psychotherapy in the treatment of depression.

Watson JC, Gordon LB, Stermac L, Kalogerakos F, Steckley P.

J Consult Clin Psychol. 2003 Aug;71(4):773-81.

PMID:
12924682
50.

Hyaluronan is not elevated in urine or serum in Hutchinson-Gilford Progeria Syndrome.

Gordon LB, Harten IA, Calabro A, Sugumaran G, Csoka AB, Brown WT, Hascall V, Toole BP.

Hum Genet. 2003 Jul;113(2):178-87. Epub 2003 May 1.

PMID:
12728312

Supplemental Content

Loading ...
Support Center